Corcept (CORT) Falls 35% as StockStory Flags Profitability, Cash Flow Concerns

Corcept Therapeutics (CORT) has dropped 35% over the six months through May 14, 2026, to $50.98, as softer quarterly results and profitability concerns weighed on investor sentiment, according to StockStory. The research firm cited three reasons for avoiding the stock: earnings per share fell 19.4% annually over the past five years despite 22.1% revenue growth, free cash flow margin declined by 31 percentage points over the same period, and return on invested capital has weakened significantly. Corcept’s trailing 12-month free cash flow margin stood at 15.6%. StockStory said the shares trade at 81.3 times forward earnings, leaving limited room for disappointment and implying much of the company’s expected growth is already priced in.